C. Ola Landgren, MD, PhD

Experts on multiple myeloma (MM) discuss factors that determine transplant eligibility for patients who are newly diagnosed.

An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.

C. Ola Landgren, MD, PhD, illustrated how minimal residual disease tracking may allow greater treatment personalization in the future.

C. Ola Landgren, MD, PhD, speaks about transplant eligibility, as well as new therapies and minimal residual disease negativity, in the multiple myeloma space.

C. Ola Landgren, MD, PhD, discusses the benefits obtained when patients have access to a full team of diverse caregivers rather than just a single physician.

C. Ola Landgren, MD, PhD, reviewed the plethora of emerging treatment options in multiple myeloma, and how unmet needs in the space can be overcome.

Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.

Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.

Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.

Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.

Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).

Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.

Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.

C. Ola Landgren, MD, PhD, discusses progression-free survival data from the phase 3 DETERMINATION trial examining lenalidomide, bortezomib, and dexamethasone with or without autologous stem cell transplant plus continuous lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Ola Landgren, MD, PhD, highlights how future research efforts in multiple myeloma are likely to focus on chemotherapy-free regimens and minimal residual disease detection.

C. Ola Landgren, MD, PhD, highlights the rationale for the phase 3 DETERMINATION trial, assessing the use of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.

After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.

Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.

Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.

In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.

A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.

Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.

Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.